W3C home > Mailing lists > Public > public-semweb-lifesci@w3.org > May 2008

Re: KB note

From: Kei Cheung <kei.cheung@yale.edu>
Date: Wed, 28 May 2008 15:39:52 -0400
To: Elizabeth Wu <ewu@alzforum.org>
Cc: kc28@email.med.yale.edu, 'Tim Clark' <twclark@nmr.mgh.harvard.edu>, "'M. Scott Marshall'" <marshall@science.uva.nl>, public-semweb-lifesci@w3.org
Message-id: <483DB508.8050206@yale.edu>

Hi Elizabeth et al.,

I just found the following document.

 
http://www.aan.com/professionals/practice/pdfs/dementia_guideline.pdf

which summarizes several guidelines with respect to detection, diagnosis, treatment, and management of dementia (e.g., alzheimer). A colleague of mine referred me to the following website (American Academy of Neurology):

http://www.aan.com

which has a full version of these guidelines. I wonder if this would be of help to classify AD patients for inclusion/exclusion in a clinical trial or to analyze patient data retropectively. I also wonder if this would be of interest to folks with clinical ontology background.

Thanks,

-Kei

Elizabeth Wu wrote:
> Hi Kei,
>
> There is an entry in the Drugs in Clinical Trials section of Alzforum on
> Huperzine A http://www.alzforum.org/drg/drc/detail.asp?id=53. The drug is
> currently in Phase IV clinical trial in China and phase II in the US.  Its
> proposed actions are linked to many of the AD hypotheses, and I would think
> that if there are sources on research on herbs that could provide more
> insight, it would be of interest to the community.
>
> Best,
>
> Elizabeth
>
> Elizabeth Wu
> Alzheimer Research Forum
>  
>
> -----Original Message-----
> From: public-semweb-lifesci-request@w3.org
> [mailto:public-semweb-lifesci-request@w3.org] On Behalf Of
> kc28@email.med.yale.edu
> Sent: Sunday, May 25, 2008 10:41 PM
> To: Tim Clark
> Cc: M. Scott Marshall; public-semweb-lifesci@w3.org
> Subject: Re: KB note
>
>
> Hi Tim et al.,
>
> I think it would be great if more details about SWAN can be added. The HCLS
> ecosystem consists of scientists, patients, doctors, government agencies,
> publishers, etc. Creating/maintaining a balance in this digital age across
> national boundaries is challenging/interesting.
>
> Speaking of national boundaries, I wonder if alternative medicine (e.g.,
> herbal
> medicine) would also be of interest to this community. For example,
> Huperzine
> is a drug derived from the herb Huperzia serrata. I also wonder if there are
> hypotheses regarding the study of herbs in the possible treatment of
> neurological diseases.
>
> Thanks,
>
> -Kei
>
>
> Quoting Tim Clark <twclark@nmr.mgh.harvard.edu>:
>
>   
>> Hi Scott,
>>
>> Your KB note lists no details about SWAN - we would like to see them
>> included.  I'll forward something to you in a separate email later
>> today.
>>
>> Best
>>
>> Tim
>>
>> Tim Clark
>> Director of Informatics, MassGeneral Institute for Neurodegenerative
>> Disease
>> Instructor in Neurology, Harvard Medical School
>> 617-947-7098 (mobile)
>>
>> On May 23, 2008, at 6:59 PM, M. Scott Marshall wrote:
>>
>>     
>>> The KB note is ready for a last round of feedback and corrections.
>>> We have until the end of the month to publish so please be speedy
>>> with feedback. You can view the Editor's working draft at:
>>>       
>> http://www.w3.org/2001/sw/hcls/notes/kb/
>>     
>>> Thanks,
>>> Scott
>>>
>>> --
>>> M. Scott Marshall
>>> tel. +31 (0) 20 525 7522
>>> http://staff.science.uva.nl/~marshall
>>> http://adaptivedisclosure.org
>>>
>>>
>>>
>>>
>>>       
>>
>>
>>     
>
>
>
>
>   
Received on Wednesday, 28 May 2008 19:40:39 UTC

This archive was generated by hypermail 2.3.1 : Wednesday, 7 January 2015 14:52:36 UTC